Diabetes drug also treats heart failure, researchers say
Dapagliflozin was found to cut death rates and hospital stays and improve patient's quality of life. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 19, 2019 Category: Consumer Health News Source Type: news
DAPA-HF Published:'Stunning Consistent Benefit With Dapagliflozin'DAPA-HF Published:'Stunning Consistent Benefit With Dapagliflozin '
Publication of trial reinforces"remarkably consistent" benefits of the SGLT2 inhibitor dapagliflozin in patients with heart failure, with or without diabetes,"bolsters confidence in the conclusions."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred
On the heels of the DAPA-HF outcomes trial, DEFINE-HF shows adding the SGLT-2 inhibitor to standard meds improved other endpoints heart failure patients care about, whether or not they had diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 18, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
FDA grants Fast Track designation for Farxiga in heart failure
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). (Source: World Pharma News)
Source: World Pharma News - September 17, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Will DAPA-HF Turn the Tide on Heart Failure? Will DAPA-HF Turn the Tide on Heart Failure?
The term gamechanger is overused but may be appropriate for the DAPA-HF trial on the SGLT2 inhibitor dapagliflozin in patients with heart failure and reduced ejection fraction. Medical conservative John Mandrola, MD, was impressed.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 6, 2019 Category: Cardiology Tags: Cardiology Expert Column Source Type: news
Diabetes treatment also reduces heart failure risk
Type 2 diabetes treatment, dapagliflozin, is also effective for reducing the risk of heart failure, according to research presented at the European Society of Cardiology conference in Paris.Times (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 2, 2019 Category: Endocrinology Source Type: news
Dapagliflozin: New HF Therapy, Even Sans Diabetes Dapagliflozin: New HF Therapy, Even Sans Diabetes
Significant reductions in heart failure events and mortality associated with the diabetes drug in the randomized trial point to a new era in the treatment of heart failure, experts say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
U.S. FDA Gives Fast Track Status to Dapagliflozin for Patients With Chronic Kidney Disease U.S. FDA Gives Fast Track Status to Dapagliflozin for Patients With Chronic Kidney Disease
AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga (dapagliflozin) to prevent heart and kidney failure in patients with chronic kidney disease (CKD), with and without diabetes.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 28, 2019 Category: Intensive Care Tags: Diabetes & Endocrinology News Source Type: news
FDA grants Fast Track designation for Farxiga in chronic kidney disease
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease (CKD). (Source: World Pharma News)
Source: World Pharma News - August 27, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Aug 23 2019 This Week in Cardiology Aug 23 2019 This Week in Cardiology
TAVR, baroreflex activation for heart failure, dapagliflozin for HF, and myocardial viability are the topics discussed by John Mandrola in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 23, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news
DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome
The SGLT2 inhibitor dapagliflozin provided significant and clinically meaningful reductions in heart failure outcomes, according to the sponsoring company.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 20, 2019 Category: Cardiology Tags: Cardiology News Source Type: news
Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically-meaningful reduction of cardiovascular death or the worsening of heart failure (defined as hospitalisation or an urgent heart failure visit), compared to placebo. (Source: World Pharma News)
Source: World Pharma News - August 20, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Diabetes patients to be offered daily tablet to curb 'runaway' blood sugar levels
Clare Blaydon-Ellis (pictured), from Hertfordshire, has been taking Forxiga for 18 months. She says she has experienced 'very few blood sugar level problems' in that time. (Source: the Mail online | Health)
Source: the Mail online | Health - July 27, 2019 Category: Consumer Health News Source Type: news
Alembic Pharma gets tentative nod from USFDA for glycemic control drug
Quoting IQVIA sales data, the company said, Dapagliflozin Tablets, have an estimated market size of USD 1.7 billion for 12 months, ending December 2018. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 22, 2019 Category: Pharmaceuticals Source Type: news
Green Light for CVD Data From DECLARE in Dapagliflozin EU Label Green Light for CVD Data From DECLARE in Dapagliflozin EU Label
The EMA CHMP gives green light to change EU label for dapagliflozin (Forxiga, AstraZeneca) for type 2 diabetes to include CV outcomes data from DECLARE-TIMI 58.International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 2, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news
